The high-affinity single nucleotide polymorphism (SNP) of the CD16 gene (158 V) is associated with a good clinical response to rituximab in rheumatoid arthritis and systemic lupus [15–17], pointing towards a role of CD16 also in the treatment of systemic inflammatory diseases. This evidence concerns the gene FCGR3A and rheumatoid arthritis.